Document Detail


Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers.
MedLine Citation:
PMID:  12923317     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Founder mutations can account for a large proportion of BRCA1/BRCA2 gene abnormalities in a given population. However there is still a need to study the entire gene in many families, even in countries where founder mutations have been identified. It is possible to decrease the number of cases which are studied by complex and expensive sequencing/Southern blot analyses of BRCA1/BRCA2 genes by exclusion of common BRCA1/BRCA2 alleles in a given family by using polymorphic dinucleotide markers. The goal of o ur study was to assess the effectiveness of this method in exclusion of BRCA1/BRCA2 constitutional mutations. In each family, blood samples for genetic analyses were taken from two affected relatives from the same generation. Six polymorphic microsatellite markers linked to BRCA1/BRCA2 genes were analysed. Results obtained with these markers were verified by applying BRCA1 testing for the most common founder mutations in Poland and using exon by exon" sequencing of coding fragments of the BRCA2 gene. Polymorphic markers useful in BRCA1/BRCA2 analyses included only 3 of 6 examined - D17S855, D13S260 and D13S267. Occurrence of commoalleles of BRCA1 was excluded in 3 families and BRCA2 in 5 out of 30 families. Results obtained by testing for BRCA1 Polish founder mutations and BRCA2 sequencing were in agreement with BRCA1 findings based on polymorphic markers. The only exception was family 994 with BRCA1 exon 5 300T/G mutation, in which BRCA1 mutation carrier was excluded by using D17S855. Among 14 families without BRCA1 Polish founder mutations in this gene were excluded in 2 families and BRCA2 mutation was excluded in one family.
Authors:
Bohdan Górski; Tadeusz Debniak; Anna Jakubowska; Cezary Cybulski; Tomasz Huzarski; Tomasz Byrski; Elzbieta Złowocka; Jan Lubiński
Related Documents :
11468277 - Spectrum of foxl2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (bpes) ...
7837387 - A collaborative survey of 80 mutations in the brca1 breast and ovarian cancer susceptib...
12543797 - Brca1/2 mutation status influences somatic genetic progression in inherited and sporadi...
17597387 - Successful use of peer educators for sharing genetic information.
14610337 - Effects of the genetic polymorphisms of the renin-angiotensin system on focal segmental...
17015357 - Ecological correlates of population genetic structure: a comparative approach using a v...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of applied genetics     Volume:  44     ISSN:  1234-1983     ISO Abbreviation:  J. Appl. Genet.     Publication Date:  2003  
Date Detail:
Created Date:  2003-08-18     Completed Date:  2003-10-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9514582     Medline TA:  J Appl Genet     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  419-23     Citation Subset:  IM    
Affiliation:
Department of Genetics and Pathology, Pomeranian Medical University, ul. Połabska 4, Szczecin 70-115, Poland. gorskib@sci.pam.szczecin.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / genetics*
Female
Genes, BRCA1*
Genes, BRCA2*
Genetic Markers
Genetic Predisposition to Disease
Humans
Mutation
Ovarian Neoplasms / genetics*
Polymorphism, Genetic
Chemical
Reg. No./Substance:
0/Genetic Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The influence of calyculin A on lymphocytes in vitro.
Next Document:  Distinct patterns of cleavage and translocation of cell cycle control proteins in CD95-induced and p...